Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3152 | Pulmonary function tests Wiki | 0.41 |
| drug3868 | TAVR or SAVR Wiki | 0.41 |
| drug1745 | Home Sleep Apnea Testing or In-hospital Polysomnography Wiki | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001049 | Apnea NIH | 0.58 |
| D001024 | Aortic Valve Stenosis NIH | 0.41 |
| D003251 | Constriction, Pathologic NIH | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D020181 | Sleep Apnea, Obstructive NIH | 0.37 |
| D012891 | Sleep Apnea, NIH | 0.37 |
| D001064 | Appendicitis NIH | 0.20 |
| D017563 | Lung Diseases, Interstitial NIH | 0.11 |
| D011658 | Pulmonary Fibrosis NIH | 0.11 |
| D009103 | Multiple Sclerosis NIH | 0.10 |
| D012598 | Scoliosi NIH | 0.09 |
| D008171 | Lung Diseases, NIH | 0.08 |
| D011014 | Pneumonia NIH | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002104 | Apnea HPO | 0.58 |
| HP:0001650 | Aortic valve stenosis HPO | 0.41 |
| HP:0002870 | Obstructive sleep apnea HPO | 0.37 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0010535 | Sleep apnea HPO | 0.37 |
| HP:0006515 | Interstitial pneumonitis HPO | 0.11 |
| HP:0002206 | Pulmonary fibrosis HPO | 0.11 |
| HP:0002088 | Abnormal lung morphology HPO | 0.08 |
| HP:0002090 | Pneumonia HPO | 0.04 |
Navigate: Correlations HPO
There are 6 clinical trials
According to recent publications, the percentage of caregivers infected with COVID 19 is evaluated between 10 and 30% . This great variability is due, on the one hand to the intensity of the influx of covid plus patients and, on the other hand, to the disparity in the preparation of caregivers in the face of this emergency. Indeed, we can understand that the strict application of hygiene rules can be faulted in the face of the volume of patients, the lack of protective equipment and the lack of specific training for caregivers in this area. As a result, within healthcare teams, there are many questions that generate anxiety: will I be able to provide care properly while protecting myself from the risk of contamination? This anxiety is also present and sometimes manifests itself aggressively in the entourage or in the vicinity of caregivers, due to lack of scientific data adapted to the local ecology of the crisis. Thus, the aim of this study is to show that the risk for caregivers of being contaminated by COVID in an area dedicated to COVID positive patients is no higher than being a caregiver in a non-COVID area that he either in the adult or pediatric sector.
Description: Participants seroconverion will be assessed by analysing IgG When the seroconverion is confirmed (whenever it occurs), the participant ends his partipation.
Measure: Seroconversion Time: Day1Description: Participants seroconverion will be assessed by analysing IgG When the seroconverion is confirmed (whenever it occurs), the participant ends his partipation.
Measure: Seroconversion Time: Day 15Description: Participants seroconverion will be assessed by analysing IgG When the seroconverion is confirmed (whenever it occurs), the participant ends his partipation.
Measure: Seroconversion Time: Day 30This is a prospective, epidemiological, cohort study to assess the feasibility of screening healthy asymptomatic workers for the presence of severe acute respiratory syndrome SARS-CoV-2 by pharyngeal swaps and serology at baseline, day 21 and day 40.
Description: Evaluation of immune responses to components of SARS-CoV-2 as well as evaluation of Swab for the presence of SARS-CoV-2 by PCR. Determination of the difference between the study groups in anti-SARS-CoV 2 seropositivity status. Analysis of trends in CD4/CD8 concentrations over time and correlation with immunoglobulin G (IgG) Levels and new assay evaluation.
Measure: Immune responses to components of SARS-Cov-2 Time: up to visit 3 (day 40)Description: Evaluation of Swab for the presence of SARS-CoV-2 by PCR and determination of the difference between the study groups in anti-SARS-CoV 2 seropositivity status.
Measure: Swabs for the presence of SARSCoV-2 Time: up to visit 3 (day 40)Description: Evaluation of immune responses to components of SARS-CoV-2 as well as evaluation of Swab for the presence of SARS-CoV-2 by PCR. Determination of the difference between the study groups in anti-SARS-CoV 2 seropositivity status and analysis of trends in CD4/CD8 concentrations over time and correlation with IgG Levels as well as new assay evaluation.
Measure: Difference between the study groups in anti-SARS-CoV 2 seropositivity status Time: up to visit 3 (day 40)COVID-19, the infectious disease caused by the novel coronavirus SARS-CoV-2, currently poses a global economic, social, political and medical challenge. The virus originated in December 2019 in Wuhan, China, and has spread rapidly around the world. Currently, European countries, including Austria, are severely affected.The most common computed tomographic changes in acute lung injury include bilateral and subpleural milk glass opacity, consolidation in lower lobes, or both. In the intermediate phase of the infection (4-14 days after the onset of symptoms) a so-called "crazy paving" may occur. The most prominent radiological changes occur around day 10, followed by gradual resolution, which begins two weeks after the onset of symptoms. Given the phylogenetic relationship between SARS-CoV-1 and SARS-CoV-2, the similar clinical course in severe cases and overlapping CT patterns in the acute setting, persistent radiological and pulmonary functional changes in survivors are conceivable. It is also conceivable that a proportion of survivors will develop progressive ILD, either due to viral or ventilator-induced alveolar damage, or both. Here, the investigators intend to investigate COVID-19 survivors through clinical examinations, functional lung examinations, HR-CT scans, and by determining the "immunofibrotic" pattern in peripheral mononuclear cells (PBMCs) 1, 3, and 6 months after discharge.
Description: Define the frequency of ILD and pulmonary vascular disease in SARS-CoV-2 infected patients with a severe/prolonged Course (inhospital stay, either on the normal ward or ICU), with and without oxygen supplementation, non-invasive or invasive ventilation) at 1 month after discharge or diagnosis of COVID-19 disease by the use of HR-CT.
Measure: Pattern of pulmonary abnormalities in SARS-CoV2 infected patients after 1 month Time: 1 monthDescription: Define the frequency of ILD and pulmonary vascular disease in SARS-CoV-2 infected patients with a severe/prolonged Course (inhospital stay, either on the normal ward or ICU), with and without oxygen supplementation, non-invasive or invasive ventilation) at 3 months after discharge or diagnosis of COVID-19 disease by the use of HR-CT
Measure: Pattern of pulmonary abnormalities in SARS-CoV2 infected patients after 3 months Time: 3 monthsDescription: Define the frequency of ILD and pulmonary vascular disease in SARS-CoV-2 infected patients with a severe/prolonged Course (inhospital stay, either on the normal ward or ICU), with and without oxygen supplementation, non-invasive or invasive ventilation) at 6 months after discharge or diagnosis of COVID-19 disease by the use of HR-CT
Measure: Pattern of pulmonary abnormalities in SARS-CoV2 infected patients after 6 months Time: 6 monthsThe recent and unexpected occurrence of patients with the development of skin lesions on the hands and/ or feet has been described recently. As these cases occurred contemporaneously with the Coronavirus Disease 2019 (COVID-19) and as it was the most often occurrence of de novo frostbites, the question raised of whether there is a direct link between the occurrence of these lesions and infection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the responsible for CoVID-19. Indeed, mechanisms of these lesions and the precise correlation with Sars-CoV-2 remains poorly understood. Therefore, this study aim to: 1. Determine the possible link with this virus, 2. Understand the mechanisms involved in the pathogenesis of these lesions.
Description: SARS-CoV-2 will be tested by Polymorphism Chain Reaction (PCR) (on the first day of consultation) and serological analysis ( at day 0 and day 15 after the first consultation)
Measure: Detection of SARS-CoV-2 by real-time PCR and serological test Time: assessing change between day 0 and day 15Description: Metagenomics analysis will be performed on nasopharyngeal, tonsil and perianal samples
Measure: Detection of SARS-CoV-2 by metagenomics analysis Time: Up to 2.5 months after inclusionDescription: Transcriptomic analysis will be conducted with RNA extracted from frozen skin samples
Measure: Detection of acrosyndrome by transcriptomic analysis of skin samples Time: Up to 2.5 months after inclusionThe purpose of this study is to analyze in depth the relationship of myeloid cell subpopulations during infection by Severe acute respiratory syndrome coronavirus 2 (SARS-Cov2), the virus mediating Covid-19. Myeloid cells include neutrophils, monocytes and dendritic cells, each divided into subpopulations with different functions in immune defense and immune pathologies. The study is based on the following hypotheses: - Infection and the interferon response to infection may induce hyperactive or immunosuppressive differentiation of myeloid cells, that may be treated by specific inhibitors. - Some myeloid cell subpopulations currently identified in our laboratories might be markers for Covid-19 prognosis. - Alternative receptors may be present on myeloid cells, inducing the cytokine storm, a target for therapy. - The expression of Interferon (IFN) receptor and IFN responding genes on myeloid cells and on respiratory epithelial cells may correlate with prognosis and indicate potential treatment targets. - Interferon responses are known to be skewed during Covid-19, but some IFN subtype polymorphisms may correlate with prognosis and these subtypes migt be supplemented or inhibited for therapy.
Description: Cytometric analysis of surface and intracellular molecules to identify myeloid cell sub-populations and define their function in vivo
Measure: Myeloid cell sub-population phenotype Time: Month zero-month 36Description: Cell culture and cytometric and analyte analysis of their functions, including IFN production
Measure: Myeloid cell functions Time: Month zero-month 36Description: Transcriptomic and proteomic analysis of the functions of myeloid cell subtypes
Measure: Myeloid cell transcriptomic and proteomic study Time: Month zero-month 36Description: Single cell RNA sequencing of the nasal brush products
Measure: Transcriptomic study of nasal epithelial cells Time: Month zero-month 36Description: High sensitivity detection by state-of-the art ELISA type methods
Measure: Plasma analyte concentration measurement Time: Month zero-month 36According to different projections, the COVID-19 outbreak currently happening in France and worldwide could result in millions of deaths in the absence of efficient therapies. The COVID-19 causative agent, the SARS-CoV-2, is a virus leading to respiratory system infections in human and for which there is currently no vaccine or treatment scientifically validated in clinical studies. In that context, therapeutic human neutralizing antibodies targeting the SARS-CoV-2 envelop glycoproteins and which enable inhibition of the viral replication represent an innovative therapeutic alternative with great potential. These antibodies are also critical tools for vaccine development. Simultaneously, CHUGA researchers coordinate with each other to set up a collective biological collection to achieve others objectives such as biomarkers identifications.
Description: Step 1 : Measurement of the monoclonal antibody concentration inhibiting 50% of the target cells infection (IC 50%) via a VSV virus pseudotyped with SARS-CoV-2 envelope glycoproteins. Neutralizing activity is defined with an IC 50 below 50 ug/ml.
Measure: Isolation of recombinant monoclonal neutralizing antibodies directed against SARS-CoV-2, isolated from COVID19 hospitalized patients blood probes. Time: From all blood sampling with serum (visit 1 at Day1, visit 6 at Day13 or, in b-group, visit 9 occuring between month 2 and month 6).Description: STEP 2 : Ability to produce monoclonal recombinant antibodies anti-SARS-CoV-2 from memory B cell (fundamental outcome : yes/no)
Measure: Isolation of recombinant monoclonal neutralizing antibodies directed against SARS-CoV-2, isolated from COVID19 hospitalized patients blood probes. Time: From patient and time frame identified in step 1 described above.Description: Blood biomarkers (IL6 in ng/L measured by flow cytometry immuno-analysis) from day 1 of hospitalization will be evaluated as potential biomarker related to worsening (defined as patient transfer to ICU or death).
Measure: Description of biological biomarkers (cytokine, IL6) predictive of worsening Time: day 1Description: Blood biomarkers (IL10 in ng/L measured by flow cytometry immuno-analysis) from day 1 of hospitalization will be evaluated as potential biomarker related to worsening (defined as patient transfer to ICU or death).
Measure: Description of biological biomarkers (cytokine, IL10) predictive of worsening Time: day 1Description: Blood biomarkers (Lymphocytes sub-populations in G/L measured by flow cytometry) from day 1 of hospitalization will be evaluated as potential biomarker related to worsening (defined as patient transfer to ICU or death).
Measure: Description of biological biomarkers (Cellular immune responses, lymphocytes) predictive of worsening Time: day 1Description: Blood biomarkers (Monocytic HLA-DR in G/L measured by flow cytometry) from day 1 of hospitalization will be evaluated as potential biomarker related to worsening (defined as patient transfer to ICU or death).
Measure: Description of biological biomarkers (Cellular immune responses, monocytes) predictive of worsening Time: day 1Description: Blood biomarkers (CH50 in % measured by spectrophotometry) from day 1 of hospitalization will be evaluated as potential biomarker related to worsening (defined as patient transfer to ICU or death).
Measure: Description of biological biomarkers (complement system, CH50) predictive of worsening Time: day 1Description: Blood biomarkers (CH50a in % measured by spectrophotometry) from day 1 of hospitalization will be evaluated as potential biomarker related to worsening (defined as patient transfer to ICU or death).
Measure: Description of biological biomarkers (complement system, CH50a) predictive of worsening Time: day 1Description: Blood biomarkers (C3 in mg/L measured by nephelometry) from day 1 of hospitalization will be evaluated as potential biomarker related to worsening (defined as patient transfer to ICU or death).
Measure: Description of biological biomarkers (complement system, C3) predictive of worsening Time: day 1Description: Blood biomarkers (C4 in mg/L measured by nephelometry) from day 1 of hospitalization will be evaluated as potential biomarker related to worsening (defined as patient transfer to ICU or death).
Measure: Description of biological biomarkers (complement system, C4) predictive of worsening Time: day 1Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports